# Presentation: 475567

## Director’s Report to the

**Director’s Report to the**
**National Advisory Council**
**on Drug Abuse**

**     ****February 4, 2009**

## Slide 2

## NIDA  BUDGET

**(Thousands)**

**Increase **
**Over **
**Prior Year**

**AIDS**

**TOTAL**

**NonAIDS**

**$698,976**

**$299,882**

**2006****Actual**

**  ****$998,858**

**-0.8%**

**2007****Budget **
**Authority**

**$699,852**
**$300,162**
**$1,000,014**
**     **

**   ****+0.6%**

**2008****Budget **
**Authority**

**   ****$703,263**
**   ****$304,032**
**$1,007,295**
**    ****+0.7%**

**2009****C.R.**

**   ****$699,168**
**   ****$301,532**
**$1,000,700**
**    ****-0.7%**

## Slide 4

## Change in NIH Leadership...

***Change in NIH Leadership...***

## Background

- June 2007 – Feb. 2008

- March 2008 – June 2008

- September 2008

**Peer Review Oversight Committee (PROC) **
**Established 4 Working Groups:**
***Engage the Best Reviewers***
***2.   Improve the Quality and Transparency of Review***
***3.   Ensure Balanced and Fair Reviews Across Scientific Fields and Career Stages ***
***4.   Evaluation:  Continuous Review of Peer Review***

**Enhancing Peer Review:**
** ****Implementation of  Recommended Actions****January 2009 *****Update***

## Priority Area 1:

**Engage the Best Reviewers**
***Enhance Reviewer Training***
**In spring 2009, ****training**** will be available to reviewers and Scientific Review Officers related to the changes in peer review.**
***Allow Flexibility through ******Virtual****** Reviews***
**Pilots will be conducted in 2009 on the feasibility of using high-bandwidth support for review meetings to provide reviewers greater flexibility and alternatives for in-person meetings.**

## Priority Area 2:

**Improve the Quality & Transparency of Review**
**Scoring to be changed to a 9 point scale with a separate assessment for impact**
**In 2009, ****streamlined applications will receive scores**** on each criterion in addition to critiques to help applicants assess whether or not they should resubmit an amended application**
**Shorten**** and Restructure Applications. Shorter (12 page research plan) R01 applications (with other activity codes scaled appropriately) for January 2010 receipt dates**
**Special considerations for ****human subjects research**** (additional material needed for clarification) **

***The review and scoring process will be changed for most applications submitted***
*** ******for January 2009 deadline and reviewers will use these new guidelines for the***
***May-June 2009 meetings.***

##         Priority Area 3:
        Ensure Balanced & Fair Reviews across Scientific Fields
        & Career Stages & Reduce Administrative Burden

 Fund Meritorious Science Earlier decreasing number 
   of resubmissions (amendments) from two to one 

 Identify Early Stage Investigators (ESIs), & establishing
   goals to encourage funding for new investigators & ESIs 

 In 2009, where possible, NIH will cluster new 
   investigator applications for review

        Priority Area 4:
        Continuous Review of Peer Review

 Evaluation group will lay foundation for continuous
    review of peer review activities

**        ****Ensure Balanced & Fair Reviews across Scientific Fields**
**        ****& Career Stages & Reduce Administrative Burden**
** ****Fund Meritorious Science Earlier decreasing number **
**   ****of resubmissions (****amendments) from two to one**** **
** ****I****dentify ****Early Stage Investigators**** (ESIs), &**** ****establishing**
**   ****goals to encourage funding for new investigators & ESIs**** **
** ****In 2009, where possible, NIH will ****cluster**** new **
**   ****investigator applications for review**
**        ****Priority Area 4:**
**        ****Continuous Review of Peer Review**
** ****Evaluation group will lay foundation for continuous**
**    ****review of peer review activities**

##  Conceived in 2004 to promote

** ****Conceived in 2004 to promote**
**  ****Consistency **
**  ****Transparency**
**  ****Reproducibility**
** ****Mandated by Congress – 2006**

**Research, Condition, and Disease **
**Categorization (RCDC) Project **

***Dr. Gaya Dowling will present on this ***
*** ******at the May 2009 Council Meeting***

## Slide 11

## Changes in Review of

**NIDA Grant Applications**

**  *****Medications Development Pre-Clinical***
***    ******Research Applications***** have been**
**    ****transferred to CSR**

**  *****Behavioral Treatment Research ***
***    ******Applications***** are in the process **
**    ****of being transferred to CSR**

## NIDA Prevention Research Review Workgroup 

**Meetings: **
- September 8-9, 2008
- February 2-3, 2009

**Final Report Due to NIDA Council: **
**May 12, 2009**

**CHAIR: **Mark T. Greenberg, Ph.D. **COUNCIL MEMBERS**
- Mary Jane Rotheram-Borus, Ph.D.
- Marina E. Wolf, Ph.D.
**ADDITIONAL SENIOR SCIENTISTS**
- Anthony Biglan, Ph.D.
- Dante Cicchetti, Ph.D.
- Phil Fisher, Ph.D.
- Marguerita Lightfoot, Ph.D.
- Michael Neale, Ph.D.
- Hilda Pantin, Ph.D.
- Irwin Sandler, Ph.D.

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Mary Affeldt**

**Associate Director for**
** ****Management**

**Mary Affeldt**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Wilson Compton, MD, MPE**

** ****AIDS Research Program**

**Special Populations Office**

**CCTN**

## CTN-0029 clinical trial designed to: 

**CTN-0029 clinical trial designed to: **
**Evaluate if treating ADHD with osmotic-release methylphenidate (OROS-MPH) vs. placebo increases the effectiveness of standard smoking treatment (i.e., nicotine patch and counseling) in adult smokers with ADHD**
**Evaluate the safety of using OROS-MPH in the treatment of smokers with ADHD**
** ****Trial completed (n=255 at 6 sites) in January 2008**
**Primary data analysis complete**
**Publication pending**

**CTN-0029: A Pilot Study of Osmotic-Release Methylphenidate (OROS-MPH) in Initiating **
**and Maintaining Abstinence in Smokers with**
**Attention Deficit Hyperactivity Disorder (ADHD) **

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Mary Affeldt**

**Associate Director for**
** ****Management**

**Mary Affeldt**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Wilson Compton, MD, MPE**

** ****AIDS Research Program**

**Special Populations Office**

**IRP**

## Dr. Hoffer will give a 

**Scientific Director Administrative Review **
**Bayview Medical Center**
**April 17 – 18, 2008**

_***Review Committee:***_**  **
**Daniele Piomelli, Pharm.D., Ph.D. (Chair)**
- Professor, Department of Pharmacology
- University of California, Irvine
**Mary Jeanne Kreek, M.D., Ph.D.**
- Professor, The Rockefeller University
**Peter W. Kalivas, Ph.D.**
- Professor and Chair, Department of Physiology & Neuroscience
- Medical University of South Carolina
**Richard Nakamura, Ph.D.**
- Deputy Director, National Institute of Mental Health
**Linda J. Porrino, Ph.D.**
- Professor, Department of Physiology and Pharmacology
- Wake Forest University School of Medicine

***Dr. Hoffer will give a ***
***response to this review***

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Mary Affeldt**

**Associate Director for**
** ****Management**

**Mary Affeldt**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Wilson Compton, MD, MPE**

** ****AIDS Research Program**

**Special Populations Office**

**DESPR**

## Percentage of U.S. 12th Grade Students 

**Percentage of U.S. 12****th**** Grade Students **
**Reporting Past Month Use of **
**Cigarettes and Marijuana, 1975 to 2008**

**CESAR *****FAX***** January 19, 2009, Vol. 18, Issue 2.**
- Adapted by CESAR from University of Michigan, “Trends in 30-Day Prevalence of Use of Various Drugs in Grades 8, 10, and 12,”Monitoring the Future study, 2008.

**Cigarettes**

**Marijuana**

**40%**
**30%**
**20%**
**10%**
**0%**

**1978     1982      1986     1990     1994     1998      2002     2006**

**1976     1980      1984     1988     1992     1996      2000     2004      2008**

##  (RFA-DA-09-007)

**Drug Abuse Epidemiology & Services Research **
**In Cooperation with the Clinical & Translational**
** ****Science Award Consortium (R01) **
**(****PAS 09-001)**
**Issued October 2, 2008**

**The Interaction of HIV, Drug Use & the**
** ****Criminal Justice System (R01)**
** ****(RFA-DA-09-007)**
**Issued: September 12, 2008**
** ****Letter of Intent Receipt Date: October 27, 2008**
**Application Due Date: November 25, 2008**

**Secondary Data Analyses for Substance**
**Abuse Research (R21/R33)**
**(RFA-DA-09-020)**
**Issued November 5, 2008**
**Letter of Intent Receipt Date: December 29, 2008**
**Application Due Date: January 28, 2009**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Mary Affeldt**

**Associate Director for**
** ****Management**

**Mary Affeldt**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Wilson Compton, MD, MPE**

** ****AIDS Research Program**

**Special Populations Office**

**DPMC**

## Search for Director, Division of Pharmacotherapies & Medical Consequences of Drug Abuse, NIDA

**Search for Director, Division of Pharmacotherapies & Medical Consequences of Drug Abuse, NIDA**

**Search Committee Chair: **
**Barry Hoffer, M.D., Ph.D., Scientific Director, NIDA**
**Vacancy Announcement # NIDA-09-304337**** **
**closes on 3/15/2009**

## Medications Development Centers 

**Medications Development Centers **
**of Excellence (P50)**
** ****(RFA-DA-09-002**** )**
**Issued August 27, 2008**
**Letter of Intent Receipt Date: November 19, 2008**
**Application Due Date: December 19, 2008**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Mary Affeldt**

**Associate Director for**
** ****Management**

**Mary Affeldt**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Wilson Compton, MD, MPE**

** ****AIDS Research Program**

**Special Populations Office**

**DBNBR**

## Central Nervous System Intersections

**Central Nervous System Intersections**
**of Drug Addiction, Chronic Pain**
** ****and Analgesia ****(R01 RFA-DA-09-017),**
**(R21 RFA-DA-09-018), (R03 RFA-DA-09-019)**
**Issued October 24, 2008**

***40 Applications Received***
- To encourage ***research on CNS changes that occur with chronic pain***, and ***how these changes parallel those that occur with drug addiction***.

**NIDA** set aside $2,000,000.  **NINDS** set aside $375,000.
**NIDCR** did not set aside money, but will consider
- funding IC-related applications

## Translating & Targeting Individual Differences 

**Biosignatures of Chronic Drug Exposure**
** ****(R21) RFA-DA-09-022**
**Issued October 1, 2008**
**Letter of Intent Receipt Date: December 29, 2008**
**Application Due Date: January 27, 2009**

**The Mouse Gene Development Initiative (R01)**
**(RFA-DA-09-015) (with NIAAA)**
**Issued October 20, 2008**
**Letter of Intent Receipt Date: December 29, 2008**
**Application Due Date: January 27, 2009**

**Behavioral Pharmacology and Genetics: **
**Translating & Targeting Individual Differences**** **
**(R03) RFA-DA-09-016**
**Issued October 1, 2008**
**Letter of Intent Receipt Date; December 29, 2008**
**Application Due Date: January 27, 2009**

**Optimization of Small Molecule Probes**
**for the Nervous System (R21)**
**(RFA-NS-09-003) (with NINDS and NIAAA)**
**Issued December 30, 2008**
**Letter of Intent Receipt Date: February 3, 2009**
**Application Due Date: March 3, 2009**

## Neuroscience Blueprint Grand Challenge Initiatives

- <date/time>

**Neuroscience Blueprint ****Grand Challenge Initiatives**

**Grand Challenge on Pain—Harnessing Our Understanding of Neural Plasticity to Elucidate the Transition From Acute to Chronic Pain**
**Grand Challenge on Imaging—Human Neuroimaging:  Seeing Connections and Molecules**
**Grand Challenge on Neurotherapeutics: New Therapies for Diseases of the Nervous System**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Mary Affeldt**

**Associate Director for**
** ****Management**

**Mary Affeldt**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Wilson Compton, MD, MPE**

** ****AIDS Research Program**

**Special Populations Office**

**DCNBR**

## Brain Imaging Drug Use

**Brain Imaging Drug Use**
**Prevention Messages (R21)**
**(RFA-DA-07-007)****  **
**DCNBR & DESPR **
**16 Applications – 3 funded**

***Goals ***** **
**  ****To validate models of health communication by identifying neural activation patterns in response to message stimuli**
**  ****To discern differences in brain and cognitive processes that lead to differential impact of media messages**
**  ****Required collaborative teams of brain imaging and prevention message investigators**

## High MSV Impedes Retention of PSAs

**High MSV Impedes Retention of PSAs**

** ****Differential Brain Activation by**
**   ****Message Sensation Value (MSV) **
** ****High MSV activated posterior**
**    ****cortex (Occipital)**
** ****Low MSV activated Prefrontal &**
**   ****Temporal Cortex**
**  ****Greater recall of Low MSV**
** ****Recall (+) corr w/Frontal &**
**   ****Temporal Pole activation**
**  ****Recall (-) corr w/post. Temporal **
**    ****Cortex**
**  ****Supports “dual processing” & **
**    “****limited capacity” theories**
** ****High MSV attenuates “deep”**
**    ****processing**

## High MSV Impedes Retention of PSAs

**  ****Greater recall of Low MSV**
**Recall (+) corr w/ Frontal &**
**      ****Temp Pole activation**
**Recall (-) corr w/ post.**
**      ****Temporal Cortex**
**  ****Supports “dual processing” & “limited capacity” theories**
**High MSV attenuates “deep” **
**      ****processing**

***Langleben, et al., Neuroimage, in press, uncorrected proof available online 14 January 2009.***

##  Transition (I/START) (R03) PAR-09-073  

**Imaging – Science Track Award for**
** ****Transition (I/START) (R03) PAR-09-073**** **** **
**Issued January 7, 2009**

**Exploratory Centers for Translational Research**
** ****on the Clinical Neurobiology of **
**Drug Addiction (P20) (RFA-DA-09-012)**
**Issued September 12, 2008**

**Brain Imaging Studies of Negative Reinforcement**
**in Humans**** ****(R01 RFA-DA-09-008) (R21 RFA-DA-09-009)**** **
**Issued November 5, 2008**
**Letter of Intent Receipt Date: January 19, 2009**
**Application Due Date: February 19, 2009**

**Neuroimaging in Obesity Research (R01)**
**(RFA-DK-08-009) (with NIDDK and NIBIB)**** **
**Issued October 9, 2008**
**Letter of Intent Receipt Date: February 18, 2009**
**Application Due Date: March 18, 2009**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Mary Affeldt**

**Associate Director for**
** ****Management**

**Mary Affeldt**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Wilson Compton, MD, MPE**

** ****AIDS Research Program**

**Special Populations Office**

**ARP**

## Pre-Application for the 2009 NIDA Avant-Garde Award

**Pre-Application for the 2009 NIDA Avant-Garde Award**
**Program for HIV/AIDS Research (X02)**
** ****PA-09-044**
**Issued: December 12, 2008**
**Application Due Date: February 27, 2009**

***X02 submissions will be reviewed by external reviewers to identify the***
*** ******most outstanding applications. Those investigators whose applications are***
***deemed to be  the most outstanding will be notified of the opportunity to***
***submit full applications under the following RFA   ***

## Epigenetics, HIV/AIDS, and Drug Abuse WorkshopThursday, January 22, 2009

**What host genes/factors are altered epigenetically by HIV infection?  **
**Do epigenetic changes associated with drug abuse affect course of HIV disease?**
**Does HIV latency and/or transcriptional silencing contribute to HIV spread, persistence or level of viremia?**
**How is virus/host interaction impacted by cell type?**
**How to integrate epigenomic, genomic, and other biological information (e.g., proteomics, metabolomics**)

_**Key Research Recommendations**_

## In this position she will be facilitating collaboration 

**In this position she will be ****facilitating collaboration**** **
**across NIDA’s Divisions, Offices and Centers **
**as well as across the NIH with an emphasis on **
**program development**** and will continue to represent**
**NIDA on a number of ****trans-NIH program teams****.  **

**Christine Colvis, Ph.D. **
- Director of Program Integration
- OD, NIDA

## Support Opportunity for Addiction Research (SOAR) 

**Support Opportunity for Addiction Research (SOAR) **
**for New Investigators (R03) **
**RFA-DA-09-021**
**Issued: December 12, 2008 (with NIAAA)****Letters of Intent Receipt Date: February 3, 2009 ****Application Due Date: March 3, 2009**** **

**These awards will ****supplement new investigators**** who have, or have a commitment**
**of, support to conduct research in basic or clinical alcohol or drug abuse research**
**from ****funding sources other than the NIH**** (e.g. private foundation).**
** **
**In addition, those applicants currently supported to conduct research on **
**psychiatric disorders that are often found to be co-morbid with **
**substance abuse, are also eligible to apply for adding a substance or alcohol abuse**
**research component to their on-going research. **

## Interactions Between Physical Activity & Drug Abuse 

**Interactions Between Physical Activity & Drug Abuse**** **
**(R01 RFA-DA-09-013) (R03 RFA-DA-014)**
**October 16-17, 2008**
**Letter of Intent Receipt Date: December 29, 2008 **
**Application Due Date: January 28, 2009**

## Addressing    

***Addressing    ***

**SUBSTANCE ABUSE &**
** ****COMORBIDITIES**

***Among Military Personnel, Veterans, ***
***& Their Families: A Research Agenda***

**Recent  epidemiological reports indicate that military **
**personnel returning from *****Operation Iraqi Freedom***** and **
***Operation Enduring Freedom *****are at higher risk for SUD**

## Meeting Held January 6-7, 2009

**Meeting Held January 6-7, 2009**
**In Collaboration with:**
***   ******U.S. Department of Defense***
**       ****U.S. Army Medical Research and Materiel Command **
**       ****Department of Defense Health Affairs**
**       ****Army Center for Substance Abuse Programs**
***   ******U.S. Department of Veterans Affairs***
***   ******Other NIH Institutes***
**       ****NIMH, NIAAA, NHLBI and NCI**

**Notes:**
Colonial Engle, Brigadier General Margaret Wilmot, Emory’s Barbara Rothbaum Demonstrates a Headmounted VR display, David Olsin and a Marcia Bray a moderator from DOD look on, Jeffrey Pyne of Arkansas VA presents on challenges conducting research with active duty individuals

## Next Steps

** ****Notice of Intent to Publish a Request for Applications**
**   ****for Trauma, Stress and Substance Use and Abuse among**
**   ****U.S. Military Personnel,  Veterans and their Families**
**   ****(NOT-DA-09-004)   was released on January 7, 2009 in**
**   ****the NIH Guide**
**  ****Report of the meeting will be on the web**
**  ****February 2, 2009 small interagency meeting held**
**   ****that included DoD, VA, NIDA, other NIH ICs and**
**   ****SAMHSA to discuss next steps**

## Slide 42

## IOM Report 

**Published July 2003**

*This bill established a *
***Scientific Management Review Board ***
*to conduct periodic organizational reviews.*
*The Board will be required to examine*
*the use of NIH's organizational authorities*
*at least every 7 years, provide a report on*
*its review, and make recommendations*
*regarding the use of such authorities. *

**National Institutes of Health**
**Reform Act of 2006  **
**Public Law 109-482***** ***

*“**The Committee provides two suggestions*
*for potential mergers for further study: *
*the merger of the National Institute on*
*Drug Abuse and the National Institute*
*on Alcohol Abuse and Alcoholism...” *